NEWS
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
Nanobiotix announced new data from Study 1100, showing disease control and tumor response in patients treated with RT-activated NBTXR3 followed by anti-PD-1 therapy for second-line or later recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). The study involved 68 heavily pre-treated patients. Results indicated a 48% overall response rate (ORR) and 76% disease control rate (DCR) in anti-PD-1 naïve patients, and a 28% ORR and 68% DCR in anti-PD-1 resistant patients. For the naïve patients, median progression-free survival (mPFS) was 7.3 months, and median overall survival (mOS) was 26.2 months. For resistant patients, mPFS was 4.2 months, and mOS was 7.8 months. The treatment showed favorable safety and feasibility, with serious Grade 3+ adverse events occurring in 8.8% of patients. These promising early efficacy signals were presented at ASCO 2024, and Nanobiotix plans further exploration in randomized trials.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1692Followers
93Following
13KVisitors
Follow